A Randomized, Placebo-Controlled, Double Blind Study of Adjuvant Cemiplimab vs Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (R2810-ONC-1788)
A Randomized, Placebo-Controlled, Double Blind Study of Adjuvant Cemiplimab vs Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (R2810-ONC-1788)
Trial Category:
Other Solid Tumor
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
